IP Library Granted Patent US 12,233,356
Granted Patent B2
US 12,233,356 · App. 17/593,613 · Granted Feb 25, 2025

Process for preparing extracellular vesicles

Inventors: Aaron Noyes (Melrose, MA); Michael Doherty (Somerville, MA); Kimberly Ellis (Somerville, MA); Raymond Bourdeau (Watertown, MA); Kayla Desanty (Bedford, MA)
Assignee: LONZA SALES AG
B01D15/362A61K39/00B01D15/363C12M29/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,233,356
App. No.
17/593,613
Granted
Feb 25, 2025
Kind
B2
Abstract

The present disclosure relates to multistep chromatographic methods for preparing extracellular vesicles (EVs). The methods were demonstrated to be effective in preparing highquality EVs in a large scale. The methods enable preparation of EVs for therapeutic and diagnostic applications, and isolation and/or sub-fractionation of EVs with desired properties for specific use.

Claims (17)

1. A method of preparing EVs comprising:

(i) subjecting a sample comprising the EVs to a depth filtration (depth-filtration processed filtrate sample);

(ii) contacting the depth-filtration processed filtrate sample to a nuclease (nuclease processed sample);

iii) contacting the nuclease processed sample to ultrafiltration and/or diafiltration (UF/DF processed filtrate sample);

(iv) contacting the UF/DF processed filtrate sample with a cation exchange chromatography (CEX) resin (CEX-processed sample);

(v) contacting the CEX-processed sample with an anion exchange chromatography (AEX) resin (AEX-processed sample);

(vi) contacting the AEX-processed sample with mixed-mode chromatography (MMC) resin (MMC processed sample); and

(vii) subjecting the MMC processed sample to a UF/DF.

2. The method of claim 1 , wherein the EVs are originated from cells comprising a transgene.

3. The method of claim 2 , wherein the transgene encodes a protein comprising an EV protein.

4. The method of claim 3 , wherein the EV protein is Prostaglandin F2 Receptor Negative Regulator (PTGFRN), Basigin (BSG), Immunoglobulin superfamily member 3 (IGSF3), Immunoglobulin superfamily member 2 (IGSF2), Integrin beta-1 (ITGB1), Integrin alpha-4 (ITGA4), 4F2 cell-surface antigen heavy chain (SLC3A2), ATP transporter, or BASP1, or a fragment or a modification thereof.

5. The method of claim 4 , wherein the EV protein is linked to a biologically active molecule.

6. The method of claim 5 , wherein the CEX resin, the AEX resin, and/or the MMC resin comprises a base matrix, wherein the base matrix is a membrane, a monolith, a hydrogel, a porous device, a nanofiber, a composite resin, or a beaded resin.

7. The method of claim 6 , wherein the base matrix comprises cellulose, agarose, polystyrene derivatives, polyvinylether, silica, methacrylate derivatives, glass, ceramic hydroxyapatite, or acrylamide.

8. The method of claim 1 , wherein the sample is obtained from perfusion cell culture, fed batch cell culture, or batch cell culture.

9. The method of claim 1 , further comprising contacting the sample with magnesium and/or EDTA.

10. The method of claim 1 , wherein the pH of the CEX loading buffer is lower than the pH of the AEX loading buffer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2023
From: NOYES, AARON; DOHERTY, MICHAEL; ELLIS, KIMBERLY; BOURDEAU, RAYMOND; DESANTY, KAYLA
To: CODIAK BIOSCIENCES, INC.
Reel/Frame 065452/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2023
From: CODIAK BIOSCIENCES, INC.
To: LONZA SALES AG
Reel/Frame 064251/0794 →
Continuity (6)
Provisional Application 62984141 · Mar 2, 2020
Provisional Application 62946895 · Dec 11, 2019
Provisional Application 62903524 · Sep 20, 2019
Provisional Application 62835436 · Apr 17, 2019
Provisional Application 62822013 · Mar 21, 2019
Related Publication 20220387906A1 · Dec 8, 2022
References Cited (14)
US 20080177048A1 · Gagnon · 2008 [cited by applicant]
US 20150353920A1 · Enderle et al. · 2015 [cited by applicant]
CN 107858324A · 2018 [cited by applicant]
WO 2012087241A1 · 2012 [cited by applicant]
WO 2016176500A1 · 2016 [cited by applicant]
WO 2017197399A1 · 2017 [cited by applicant]
WO 2020027185A1 · 2020 [cited by applicant]
Zhang, et al., Biochem Biophys Res Commun. Feb. 8, 2008; 366(2): 579-584 (Year: 2008). [cited by examiner]
Choudhary et al., “[3] Ion-Exchange Chromatography,” Methods in Enzymology. vol. 2711 (Year: 1996). [cited by examiner]
International Search Report in PCT/US2020/024038, ISA EPO, dated Oct. 8, 2020. [cited by applicant]
Kim et al., “Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI,” PNAS 113(1): 170-175 (2016). [cited by applicant]
Tengattini, “Chromatographic Approaches for Purification and Analytical Characterization of Extracellular Vesicles: Recent Advancements,” Chromatographia 82(1): 415-424 (2018). [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action in U.S. Pat. No. 18,050,011, dated Mar. 29, 2024. [cited by applicant]
United States Patent and Trademark Office, Final Office Action in U.S. Appl. No. 18/050,011, dated Oct. 10, 2025. [cited by applicant]